Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1503099
This article is part of the Research Topic Immunotherapy Resistance and Advancing Adaptive Cell Therapeutics View all 4 articles

Breaking Barriers: Advancing Cellular Therapies in Autoimmune Disease Management

Provisionally accepted
Yanhong Fu Yanhong Fu 1Chunjing Feng Chunjing Feng 1Shan Qin Shan Qin 1Zhiyao Xing Zhiyao Xing 2Chong Liu Chong Liu 1*Zichuan Liu Zichuan Liu 1*Hongjian Yu Hongjian Yu 2*
  • 1 Tianjin University, Tianjin, China
  • 2 Jinnan Hospital, Faculty of Medicine, Tianjin University, Tianjin, China

The final, formatted version of the article will be published soon.

    Autoimmune diseases occur due to a dysregulation within the immune system, leading to an aberrant assault on the organism's own tissues. The pathogenesis of these conditions is multifactorial, encompassing intricate interplays among genetic predispositions, environmental determinants, and hormonal fluctuations. The spectrum of autoimmune diseases is broad, impacting a multitude of organ systems, with notable examples such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), psoriasis, and vitiligo. Despite substantial progress in therapeutic interventions over recent years, a definitive cure for autoimmune diseases has yet to be realized, with existing modalities largely providing palliative care. Cellular therapy is considered the fourth pillar in the management of oncological disorders subsequent to surgical resection, radiotherapy, and chemotherapy. Cellular therapies have shown potential in augmenting immune competence and eliminating of targeted neoplastic cells in a spectrum of cancers. As targeting specific molecules on the surface of autoreactive B and T cells, such as CD19, BCMA, CD20, and CTLA-4, cellular therapies are emerging as promising approaches for the treatment of autoimmune diseases. This review delineates the advancements in the application of cellular therapies applied recently for autoimmune diseases and proposes considerations for the advancement of novel therapeutic strategies.

    Keywords: Autoimmune Diseases, cellular therapy, B cells, CD19, Tregs

    Received: 28 Sep 2024; Accepted: 11 Nov 2024.

    Copyright: © 2024 Fu, Feng, Qin, Xing, Liu, Liu and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Chong Liu, Tianjin University, Tianjin, China
    Zichuan Liu, Tianjin University, Tianjin, China
    Hongjian Yu, Jinnan Hospital, Faculty of Medicine, Tianjin University, Tianjin, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.